– Biotricity is developing the Bioflux remote cardiac monitoring system that could disrupt the $22 billion cardiac monitoring market.
– U.S. FDA and CMS recently announced improved reimbursement for remote monitoring devices such as BTCY’s.
– USFDA clearance of Bioflux could come as soon as next week and BTCY should make a big move when announced.
– Companies like BTCY are positioned to benefit from a massive shift towards high-tech, high-value products like this device.
Between the United States Food and Drug Administration (USFDA) and the Centers for Medicare & Medicaid Services (CMS), the signals are all there – remote patient monitoring is on the verge of a major market expansion, and Biotricity (OTCMKST:BTCY) exemplifies the kind of company that can benefit. Biotricity’s Bioflux remote cardiac monitor is …View the full post at: Here’s Why Biotricity (BTCY) Could Make A Similar Move to Madrigal (MDGL) and Digital Power (DPW) …
Related Articles:
Canadian Junior Miners Seeing Major Increase in Value
The Top 7 Jurisdictions Likely to Legalize Nutrients in 2018
Option Trading Before Earnings in Micron Technology (MU)
800 Percent Revenue Growth Could Imply 200-300 Percent Returns For This Small Cap Stock
